Juno Therapeutics Inc. (JUNO) 52.84 $JUNO How Alan Leong

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Juno Therapeutics Inc. (JUNO) 52.84 $JUNO

How Alan Leong Of BioWatch News Keeps Successful Biotech Investing Simple
Life Sciences Report - Seeking Alpha - Thu Mar 05, 4:53PM CST
Biotechnology can be daunting to comprehend, but understanding is critical to successful investment. BioWatch News Founder Alan Leong has a nose for growth names, and his goal is to make their technology platforms clear to investors who might not...
CTRV: 4.61 (-0.19), GLMD: 9.29 (-0.33), PTBI: 3.50 (-0.05), CNAT: 6.05 (-0.54), GALT: 3.71 (+0.02), SRNE: 13.63 (+0.03), CELG: 118.03 (-2.68), GILD: 101.81 (-1.61), KITE: 66.41 (+1.44), CFRX: 4.61 (+0.28), ICPT: 266.14 (+4.96), JUNO: 52.84 (+0.81), CORT: 3.42 (-0.19)

AbbVie's high-priced takeout of Pharmacyclics bodes well for other biotechs with high potential drugs
Seeking Alpha - at Seeking Alpha - Thu Mar 05, 7:52AM CST

VRTX: 126.34 (-0.62), PCYC: 254.56 (+0.34), BMRN: 113.77 (+0.27), UTHR: 160.65 (-0.71), AMGN: 154.88 (-4.72), DYAX: 15.64 (-0.05), JNJ: 100.11 (-2.41), ESPR: 65.28 (+2.12), KITE: 66.41 (+1.44), RCPT: 140.09 (-1.10), PTCT: 71.13 (-1.59), ICPT: 266.14 (+4.96), ABBV: 55.64 (-1.22), JUNO: 52.84 (+0.81), SNY: 47.42 (-0.94)

Wall Street's Current Play: 'Immunotherapy Of Cancer'
Chris Lacoursiere - at Seeking Alpha - Thu Feb 26, 10:39AM CST

KITE: 66.41 (+1.44), PPHM: 1.63 (+0.06), JUNO: 52.84 (+0.81)

Immuno-Oncology Promises Continued Wealth And Health: LifeTech Capital's Stephen Dunn
Life Sciences Report - Seeking Alpha - Fri Feb 20, 11:11AM CST
Immuno-oncology-disabling cancer's defenses so that a patient's own immune system can seek it out and destroy it-took center stage in the drug development world in 2014. Stephen Dunn of LifeTech Capital believes that preeminence will continue in...
BLCM: 24.48 (+0.13), KITE: 66.41 (+1.44), PFE: 33.97 (-0.50), MRK: 56.84 (-1.14), JUNO: 52.84 (+0.81), BMY: 65.12 (-0.93), CBMG: 33.99 (+1.60), NVS: 97.46 (-1.49)

5 Stocks Ready for Breakouts: Juno Therapeutics, Cheetah Mobile and More
at The Street - Fri Feb 20, 6:00AM CST
These stocks look poised to break out and trade higher from current levels.
CMCM: 18.39 (+0.54), JUNO: 52.84 (+0.81), BAA: 0.19 (-0.03), OCLS: 0.95 (+0.01), ZAGG: 8.53 (-0.07)

Be Careful: These Biotechs Have Run Too Far Too Fast
Motley Fool Staff - Motley Fool - Mon Feb 16, 10:13AM CST
In biotechnology, stocks sometimes get a bit too far in front of themselves. When that happens, shares can take a big dip; so we asked three Motley Fool experts to weigh in on which stocks they think have climbed too much, too quickly. : On the...
JNJ: 100.11 (-2.41), PCYC: 254.56 (+0.34), JPM: 60.89 (-1.11), GILD: 101.81 (-1.61), KITE: 66.41 (+1.44), ABBV: 55.64 (-1.22), JUNO: 52.84 (+0.81), NVS: 97.46 (-1.49), CELG: 118.03 (-2.68)

'Mad Money' Lightning Round: Just Say No to Conoco Stock
at The Street - Fri Feb 13, 5:00AM CST
Cramer wants to own FreshPet and prefers Pepsico over Dr Pepper Snapple.
FRPT: 17.85 (+0.37), COP: 62.79 (-0.54), DIS: 103.82 (-1.21), XRX: 13.14 (-0.38), CELG: 118.03 (-2.68), PEP: 96.17 (-1.06), DPS: 78.35 (-0.55), ISIS: 70.44 (-1.32), TSRA: 39.92 (+0.26), JUNO: 52.84 (+0.81), SPLK: 62.48 (-2.17), DATA: 92.34 (-3.16), REGN: 422.13 (-6.82)

Disney Is A Long-Term Buy - Cramer's Lightning Round (2/12/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Fri Feb 13, 4:32AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, February 12. Bullish Calls: Xerox (NYSE: XRX ): "The last quarter was not good and the stock should have gone down," said Cramer. He thinks...
FRPT: 17.85 (+0.37), COP: 62.79 (-0.54), DIS: 103.82 (-1.21), XRX: 13.14 (-0.38), PEP: 96.17 (-1.06), CELG: 118.03 (-2.68), DPS: 78.35 (-0.55), ZTS: 45.78 (-0.68), HALO: 15.20 (-0.19), ISIS: 70.44 (-1.32), TSRA: 39.92 (+0.26), MRK: 56.84 (-1.14), JUNO: 52.84 (+0.81), SPLK: 62.48 (-2.17), REGN: 422.13 (-6.82)

Jim Cramer's 'Mad Money' Recap: Buy the Best and Leave the Rest
at The Street - Thu Feb 12, 7:12PM CST
Rarely does the market put the winning lottery ticket right in front of you, but today's winners were hiding in plain sight, Cramer says.
WFM: 55.66 (-0.49), MLM: 140.69 (-1.77), D: 69.58 (-1.60), TSLA: 193.88 (-6.75), FRPT: 17.85 (+0.37), SKX: 66.79 (-1.65), TRIP: 85.70 (-2.28), COP: 62.79 (-0.54), DIS: 103.82 (-1.21), XRX: 13.14 (-0.38), OWW: 11.69 (+0.02), PEP: 96.17 (-1.06), CELG: 118.03 (-2.68), WWAV: 41.79 (-0.63), DPS: 78.35 (-0.55), ISIS: 70.44 (-1.32), TSRA: 39.92 (+0.26), EXPE: 90.25 (-1.13), JUNO: 52.84 (+0.81), SPLK: 62.48 (-2.17), DATA: 92.34 (-3.16), AAPL: 126.60 (+0.19), REGN: 422.13 (-6.82), CSCO: 28.92 (-0.38)

NeoStem: The Levi Strauss Of Cell Therapy
Patrick Young - at Seeking Alpha - Thu Feb 12, 8:05AM CST

OCAT: 6.63 (+0.01), VCEL: 3.65 (-0.02), PSTI: 3.10 (-0.11), NBS: 3.79 (-0.18), GSK: 46.73 (-0.87), IMUC: 0.59 (-0.01), KITE: 66.41 (+1.44), BAX: 67.73 (-1.48), ONCE: 58.01 (+0.48), JUNO: 52.84 (+0.81), ATHX: 2.98 (+0.10), CUR: 3.79 (+0.02)

Momentum Indicators for Biotech Equities - PDL BioPharma, Geron, Celldex Therapeutics, XOMA Corp., and Juno Therapeutics
PR Newswire - Mon Feb 09, 8:05AM CST
Investor-Edge has initiated coverage on the following equities: PDL BioPharma Inc. (NASDAQ: PDLI), Geron Corporation (NASDAQ: GERN), Celldex Therapeutics Inc. (NASDAQ: CLDX), XOMA Corporation (NASDAQ: XOMA), and Juno Therapeutics Inc. (NASDAQ: JUNO). Free research report on PDL BioPharma can be accessed at http://get.Investor-Edge.com/pdf/?c=PDL%20Bio...amp;s=PDLI. On Friday, February 06, 2015, the NASDAQ Composite ended at 4,744.40, down 0.43%, the Dow Jones Industrial Average declined 0.34%, to finish the day at 17,824.29, and the S&P 500 closed at 2,055.47, down 0.34%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 806.81, down 0.84%, while the index has advanced 4.07% in the last three months. Register for your complimentary reports at the links given below.
GERN: 3.50 (-0.28), CLDX: 29.39 (-0.39), JUNO: 52.84 (+0.81), XOMA: 3.57 (-0.08), PDLI: 6.70 (-0.40)

Juno Therapeutics Establishes Manufacturing Presence in Washington State
GlobeNewswire - Mon Feb 09, 7:06AM CST
Juno Therapeutics, Inc. (Nasdaq:JUNO) today announced that it has entered into a lease agreement for a facility in Bothell, Washington to manufacture the company's cell therapy products. The facility, which is expected to come online in early 2016, will support Juno's planned JCAR015 multicenter clinical trial, additional clinical programs in Juno's pipeline, and the company's first commercial products.
JUNO: 52.84 (+0.81)

Not For The Faint Of CAR-T: The CAR-T Landscape In Early 2015
EP Vantage - Seeking Alpha - Fri Feb 06, 1:26PM CST
This is an extract from a longer report. If you followed last year's explosion of enthusiasm in CAR therapies you might have assumed that this was a super-novel approach that had just burst onto the scientific stage. In fact work on the synthetic...
BLUE: 113.14 (+0.91), CLRB: 2.59 (+0.08), BLCM: 24.48 (+0.13), KITE: 66.41 (+1.44), JUNO: 52.84 (+0.81), NVS: 97.46 (-1.49)

Biotechs and Drugmakers Expected to Seek More Mergers in 2015
at The Street - Fri Feb 06, 12:23PM CST
The perceived risk from macroeconomic issues — such as those in Europe — as well as changes in both interest rates and oil prices will make outright sales more attractive.
RDUS: 47.47 (+1.29), JUNO: 52.84 (+0.81)

Northwest Has A Differentiated Technology Platform In The Emerging Immuno-Oncology Landscape
Smith On Stocks - Seeking Alpha - Fri Feb 06, 11:08AM CST
Investment Overview Linda Powers was invited to the 7th Annual Phacilitate Immunotherapy Forum in Washington D.C. to speak on the potential role of personalized immunotherapy drugs in the treatment of cancer. She was prominently featured in the ...
NWBO: 7.50 (+0.14), KITE: 66.41 (+1.44), JUNO: 52.84 (+0.81)

Critical Alerts For Juno Therapeutics Inc, Westport Innovations, Disney, Twitter and Celgene Released By InvestorsObserver
PR Newswire - Thu Feb 05, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for JUNO, WPRT, DIS, TWTR and CELG.
WPRT: 5.16 (-0.21), DIS: 103.82 (-1.21), JUNO: 52.84 (+0.81), TWTR: 46.75 (-0.60), CELG: 118.03 (-2.68), CELGZ: 3.21 (unch)

Juno Therapeutics to Present at 2015 Leerink Global Healthcare Conference
GlobeNewswire - Thu Feb 05, 7:07AM CST
Juno Therapeutics, Inc. (Nasdaq:JUNO) today announced that it will webcast its presentation at the 2015 Leerink Global Healthcare Conference at 2:40 p.m. EST, Wednesday, Feb. 11, 2015. The presentation will feature a business overview and update by Steve Harr, Chief Financial Officer of Juno.
JUNO: 52.84 (+0.81)

Immuno-Oncology Is The Future Of Cancer Treatment: My Money Is On Juno Therapeutics
Stock Doctor - Seeking Alpha - Wed Feb 04, 11:03AM CST
Biotechnology investors are well aware of the emerging cancer cellular immunotherapy treatments in which the body's own immune system is used to target and kill cancer cells. To date, these therapies have shown astonishing results in small scale...
JUNO: 52.84 (+0.81), NVS: 97.46 (-1.49)

Bellicum Pharmaceuticals: Has The Bell Finally Tolled For Cancer?
Looking For Diogenes - at Seeking Alpha - Mon Feb 02, 2:43PM CST

BLUE: 113.14 (+0.91), BLCM: 24.48 (+0.13), KITE: 66.41 (+1.44), JUNO: 52.84 (+0.81), NVS: 97.46 (-1.49), CELG: 118.03 (-2.68)

Dendreon's Asset Rummage Sale Completes the Circle of Life
at The Street - Fri Jan 30, 5:01AM CST
Valeant Pharmaceuticals is in a tentative deal to acquire the assets of Dendreon -- mostly its prostate-cancer vaccine Provenge and manufacturing facilities -- for $296 million in cash.
VRX: 198.71 (-5.24), JUNO: 52.84 (+0.81)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

MISUMI Americas Expands, Ventures into New Horizons

Updated Category News Views 119

Marking New Territory in Monterrey MISUMI Americas is planting a new flag down in Monterrey, Mexico, with a sprawling 45,000-square-foot facility. This isn't just another expansion; it's a strategic move that's bound to shake things up in the manufacturing sector south of the border. When you've got a player like MISUMI widening their footprint, it catches the eye. Why?...

Continue Reading
Neil deGrasse Tyson Headlines HIMSS27 with Cosmic Insights

Updated Category News Views 188

celebrated science communicator, is set to close out the HIMSS27 conference with a keynote that's bound to leave a lasting impression. It's a fitting intersection of stars and stethoscopes, as the astrophysicist brings his expansive lens to the nitty-gritty of healthcare innovation. Splicing Science with Storytelling Folks, this ain't your standard healthcare gathering....

Continue Reading
Sovereign Crown Vault's Auction Draws Numismatic Collectors

Updated Category News Views 82

A Legendary Auction with Three Generations of Passion Coins, eh? They might just be small metallic disks to the untrained eye, but these suckers tell stories that stretch beyond any bank ledger. Sovereign Crown Vault LLC knows this, and they’re gearing up for quite the show on November 22, 2026. Their Holiday Season Kickoff Spectacular is about to lure in collectors...

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 88

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading
Gary Brecka's Longevity Centers Set to Launch with Impact

Updated Category News Views 114

A Footprint of Longevity in the Making It's not every day you see a name like Daymond John, of Shark Tank fame, getting his hands into the business of human longevity. But here we are, with Gary Brecka's Ultimate Longevity Center (ULC) getting ready to open its first centers come January 2027, in Arizona, Colorado, Florida, and Southern California. More than 300 U.S....

Continue Reading
SGRY Acquisition Under Scrutiny: Fairness Questioned

Updated Category News Views 185

Questions Hover Over SGRY Acquisition Here's a real jaw-dropper for you. Surgery Partners, Inc. (NASDAQ: SGRY) is getting clocks cleaned in a fairness probe over its acquisition terms. If you thought this ride was smooth, think again—Levi & Korsinsky, LLP has put the brakes on any such assumptions, launching an investigation that’s sure to raise some eyebrows. What's...

Continue Reading
MacKenzie-Childs Grinds Into Spotlight with Oprah's Nod

Updated Category News Views 69

Oprah's Golden Touch: 30 Years Strong Every year, there are a few select spots that brands covet like a hawk on a rabbit hunt. Getting on Oprah’s 'Favorite Things' list is surely one of them. Just like that, the MacKenzie-Childs Electric Salt and Pepper Grinder Set has muscled its way into the 2026 selection. Spare me the bells and whistles; this is like hitting the...

Continue Reading
Norris Lake's New Kayak Fleet Propels Tourism Efforts

Updated Category News Views 120

Norris Lake Doubles Down on Water Adventures The winds of change are paddling through Norris Dam State Park as they've launched a new fleet of shiny kayaks, hoping to lure more adventure seekers into the heart of Tennessee. These ain't just boats; they're part of a bigger play by local tourism honchos hungry to pump some adrenaline—and dollars—back into the area. A...

Continue Reading
S&P Global's Bold $2 Billion Debt Offering Details

Updated Category News Views 80

Drilling Down into S&P Global's Debt Move S&P Global's throwing its hat in the ring with a colossal $2 billion debt offering. Now, they aren't just setting it on the table — they're notably carving it up into three chunks. You’ve got $750 million at 5.600% that comes due in 2031, $600 million at 5.800% for 2034, and $650 million at a 6.000% rate maturing in 2036....

Continue Reading
AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 125

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading

Top 5 Most Recently Viewed Articles

Preliminary Ratings Issued by KBRA for Upstart Securitization Trust

Updated Category News Views 388

Preliminary Ratings by KBRA for Upstart Securitization Trust 2024-1 KBRA recently assigned preliminary ratings to the three classes of notes issued by Upstart Securitization Trust 2024-1, also known as UPST 2024-1. This securitization involves a notable value of $208.001 million, primarily revolving around unsecured consumer loans. Details of the Ratings The assigned...

Continue Reading
Alchemy Pay Expands With Mississippi License Milestone

Updated Category News Views 247

Alchemy Pay's Latest Regulatory Push Well, here's something to chew on—Alchemy Pay, that stalwart in the fiat-crypto payment arena, just nabbed a Money Transmitter License down in Mississippi. Good move, because this means they've got their hands now in 20 states across the U.S. Quite a feat for a company out of Hong Kong looking to make waves in the regulatory ocean....

Continue Reading
Optimi Health Steps Up with Microdose Psilocybin

Updated Category News Views 27

New Horizons in the World of Psychedelics Optimi Health has just dropped a noteworthy update, and it's not something to ignore if you're keeping an eye on the psychedelic sector. They're rolling out microdose psilocybin products — a move that’s poised to stir the waters in clinical research. With dosages standardized at 1mg and 2mg, Optimi is targeting the need for...

Continue Reading
PowerBank Corporation Sees Stock Surge After Funding News

Updated Category News Views 111

PowerBank Corporation Stock Surge PowerBank Corporation (NASDAQ: SUUN) experienced significant stock gains recently, particularly on Wednesday. This rise came after the company announced an initial payment of $4 million for its solar projects, including Elmira, Jordan Road 1, and Jordan Road 2. This financial boost has attracted investor interest and propelled the stock...

Continue Reading
Lazard's Q3 2026: Surging Revenue, Waning Net Income

Updated Category News Views 88

Breaking Down the Numbers Lazard just dropped its Q3 2026 earnings report, and you can smell both optimism and caution in the air. Sure, $814 million in net revenue isn’t anything to sneeze at, especially when it’s a neat 9% jump from last year’s $748 million. Adjusted figures were a whisker away at $805 million. But dig deeper, and things get a tad less rosy—net...

Continue Reading